1
EXHIBIT 10.33
DIVERSITY LIBRARY SCREENING AGREEMENT
This DIVERSITY LIBRARY SCREENING AGREEMENT (the "Agreement"), effective
as of June 8, 1999 (the "Effective Date"), is made by and between Array
BioPharma Inc., a Delaware corporation having its principal offices located at
0000 00xx Xxxxxx, Xxxxxxx, XX 00000 ("Array"), and Tularik Inc., a Delaware
corporation, having a principal place of business at Xxx Xxxxxxxxx Xxxxx, Xxxxx
Xxx Xxxxxxxxx, XX 00000 ("Tularik").
BACKGROUND
A. Array has developed novel proprietary methods for the generation of
compound libraries.
B. Array and Tularik have entered into a Preview Library Agreement
effective as of February 22, 1999 (the "Preview Library Agreement") pursuant to
which Array transferred to Tularik a certain library of compounds for screening
and evaluation, all as set forth therein.
C. Tularik now desires to obtain certain additional compound libraries
for screening to identify candidate compounds for further evaluation and at
Tularik's option to further optimize such compounds, all on the terms and
conditions set forth below.
NOW, THEREFORE, for and in consideration of the covenants, conditions,
and undertakings hereinafter set forth, it is agreed by and between the parties
as follows:
DEFINITIONS
1.1 "Active Compound" shall mean a Compound that Tularik shall
have the exclusive right to develop and commercialize pursuant to the exclusive
license granted in Section 3.1(a)(ii) below, provided that Tularik has
designated the same as an Active Compound pursuant to Section 3.2 below and is
paying, or has paid, each Annual Maintenance Fee for the same pursuant to
Section 3.3 below.
1.2 "Annual Maintenance Fee" shall have the meaning as set
forth in Section 3.3(a) below.
1.3 "Array Invention" shall have the meaning as set forth in
Section 3.4(a) below.
1.4 "Collaboration" shall mean an arrangement between Tularik
and a third party that is focused on the discovery or development of drugs for
specified diseases or targets, under which Tularik either retains rights to
commercialize the resulting products or will receive a portion of the sales of
the resulting products from the other party (by way of royalty, profit
participation or similar mechanism).
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
2
1.5 "Compound" shall mean each chemically distinct compound
which is contained in the Diversity Library or the Second Diversity Library
provided to Tularik by Array under this Agreement.
1.6 "Diversity Library" shall have the meaning set forth in
Section 2.1.
1.7 "Explosion Agreement" shall have the meaning set forth in
Section 2.3.
1.8 "Field" shall mean any and all therapeutic applications.
1.9 "FTE" shall mean a full-time scientific/technical employee
or the equivalent thereof.
1.10 "FTE Week" shall mean the amount of time one FTE would
spend working during one work week, i.e., five (5) calendar days.
1.11 "Licensed Technology" shall mean Array Patent Rights and
Know-How. Notwithstanding the foregoing, it is understood that Licensed
Technology shall not include any patent or other rights to high-speed synthesis
technology, methods or compound libraries (except the Diversity Library or
Second Diversity Library delivered hereunder).
(a) "Array Patent Rights" shall mean Array's rights
in (i) any patent or patent application filed by Array covering an Array
Invention that claims an Active Compound, the method of use or process for the
synthesis of an Active Compound or composition-of-matter containing an Active
Compound, for which the earliest effective filing date is prior to the end of
the Selection Period for such Active Compound and (ii) any divisions,
continuations, continuations-in-part, reissues, reexaminations, or extensions to
the extent the same have an earliest effective filing date prior to the date
described in clause (i) above, and any substitutions, confirmations or
registrations of any of the foregoing that are owned by Array, to the extent
Array has the right to license or sublicense the same.
(b) "Know-How" shall mean synthetic protocols used
for the synthesis of the Compounds, any technical information, know how,
process, procedure, composition, device, method, formula, technique, software,
design, drawing or data directly relating to the Compounds.
1.12 "Public Domain Compound" shall mean a Compound that
cannot be claimed as a composition of matter in a patent application because of
failure to meet the requirements for patentability under U.S. patent law (i.e.,
35 U.S.C. et seq.).
1.13 "Re-Supply Compound" shall have the meaning as set forth
in Section 2.2 below.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
3
1.14 "Scaffold" shall mean the core chemical structure of the
Compounds within a TA Library.
1.15 "Second Diversity Library" shall have the meaning set
forth in section 2.10.
1.16 "Selection Period" shall mean, for a particular Compound,
the period commencing upon the first delivery of such Compound to Tularik and
ending on the date five (5) years thereafter.
1.17 "Template Array Library" or "TA Library" shall mean a
library of related yet distinct Compounds delivered to Tularik by Array under
this Agreement.
1.18 "Termination Notice" shall mean a writing that identifies
an Active Compound for which Tularik is terminating its designation as an Active
Compound in accordance with Section 3.7 below.
2. DIVERSITY LIBRARY
2.1 Diversity Library. Subject to the terms and conditions of
this Agreement, Array shall deliver to Tularik the small molecule compound
library described in this Section 2.1 (the "Diversity Library") on a
nonexclusive basis. The Diversity Library shall consist of [ * ] TA Libraries
and shall contain a total of [ * ] Compounds. Each TA Library shall contain on
average [ * ] of each Compound, and each Compound within a TA Library shall be
based on the same Scaffold. The TA Libraries shall be based on the Scaffolds set
forth on Exhibit A, or such other Scaffolds as the parties may mutually agree in
writing. Each of the Compounds shall conform to the specifications and meet the
quality control criteria set forth on Exhibit B.
2.2 Additional Quantities. Subject to the terms of this
Section 2.2 below, Tularik shall have the option to obtain additional quantities
of any Compound already delivered hereunder as part of a TA Library
(collectively, "Re-Supply Compounds"), by written order to Array specifying the
Compound(s) desired, together with a complete description of the chemical
structure and the amount desired (i.e., [ * ])
(a) [ * ] . With respect to [ * ] quantities of
Re-Supply Compounds, the cumulative number of such Re-Supply Compounds that
Tularik has ordered at any given time shall in no event exceed [ * ] of the
total number of Compounds delivered hereunder, in the aggregate, as of the date
of such order, and no more than one (1) such re-supply order may be made in any
[ * ] . Tularik shall pay [ * ] for each such Re-Supply Compound (i.e., [ * ]
quantities) delivered hereunder. Unless otherwise agreed, the same compound
shall not be re-supplied to Tularik more than once under this Section 2.2(a).
(b) [ * ]. With respect to [ * ] quantities of
Re-Supply Compounds, the cumulative number of such Re-Supply Compounds that
Tularik ordered at any given time shall in no event exceed [ * ] compounds in
any given [ * ] day period. Tularik shall pay [ * ] FTE
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
4
Week for re-synthesis of Re-Supply Compounds, but in no event shall Tularik pay
more than [ * ] for each such Re-Supply Compound (i.e., [ * ] quantity)
delivered hereunder.
Array shall deliver [ * ] quantities of a Re-Supply Compound
(if in stock) within [ * ] business days of Array's receipt of Tularik's order.
If Array has to re-synthesize a Re-Supply Compound then Array shall use good
faith efforts to deliver Re-Supply Compounds to Tularik within [ * ] of Array's
receipt of Tularik's order therefor, and each Re-Supply Compound supplied
hereunder shall comply with the applicable specifications of Exhibit B. Array's
obligation to deliver Re-Supply Compounds shall continue for a period of [ * ]
following the delivery of the Diversity Library or the Second Diversity Library,
as the case may be, unless this Agreement is earlier terminated by Array for
breach by Tularik.
2.3 [ * ]. Upon Tularik's written request, the parties shall
negotiate the term and conditions of an - agreement based on the term sheet
attached hereto as Exhibit C (each an "Explosion Agreement") with respect to a
particular Compound for which Tularik desires to obtain access to an [ * ] all
as to be set forth in the Explosion Agreement; provided that, unless Array
otherwise agrees in writing Array shall have no obligation to enter into an
Explosion Agreement with respect to more than [ * ] at the same time. Such a
request shall: (i) be given prior to the expiration of the Selection Period for
the particular Compound that is to be the subject of the Explosion Agreement,
(ii) reference this Section 2.3 and (iii) designate the Compound (including a
complete description of its chemical structure) that is to the be subject of the
Explosion Agreement . In such case the parties shall negotiate for a period of
[ * ] and, if for any reason the parties are unable to execute a definitive
Explosion Agreement with respect to a particular Compound within such [ * ]
period, neither party shall have any further obligation under this Section 2.3
with respect to such Compound thereafter.
2.4 Compound Information. Together with each TA Library
delivered hereunder, Array shall provide to Tularik the following Compound
Information for the Compounds in such TA Library: (i) structural data for each
Compound; (ii) plate location coordinates and an identification number for each
Compound; and (iii) [ * ] (collectively, the "Compound Information").
In addition, Array shall make available a copy of the quality control data and
methods used for each TA Library delivered hereunder.
2.5 Delivery. Array shall use good faith efforts to deliver
each TA Library in accordance with a schedule mutually agreed upon by the
parties. Each TA Library shall be delivered [ * ] to Tularik's address set forth
above (or such other address as Tularik may specify in writing prior to the
shipping date therefor). The carrier shall be selected by agreement between
Array and Tularik, provided that in the event no such agreement is reached
Tularik shall select the carrier.
2.6 Price. Except as set forth in Section 2.2 with respect to
Re-Supply Compounds, the price to be paid by Tularik for Compounds actually
delivered in accordance with this Agreement shall be [ * ] , payable as follows:
(i) within thirty (30) days of the Effective Date, Tularik shall pay to Array
[ * ] (i.e., [ * ] of the estimated total price of the
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
5
Diversity Library) and (ii) the balance (i.e., [ * ] ) upon Tularik's receipt of
such Compound. In the event that Tularik reasonably demonstrates to Array that
any Compound does not conform to the specifications and meet the quality control
criteria set forth on Exhibit B, Array shall either: (A) offset future payments
due under Section 2.6(ii) by the amount previously paid by Tularik relating to
every such non-conforming Compound; or (B) refund to Tularik the amount
previously paid by Tularik relating to every such non-conforming Compound.
2.7 Payment. Together with each shipment of Compounds
hereunder, Array shall submit an invoice to Tularik therefor. Each invoice shall
state the total invoiced amount and the number of Compounds included in a
particular shipment, plus any insurance, taxes or other costs incident to the
shipment or delivery of Compounds hereunder [ * ] . All payments hereunder shall
be made in U.S. Dollars, by direct bank transfer to an account designated in
Array's invoice, within [ * ] days after Tularik's receipt of the particular
shipment. Any payments hereunder that are not paid on the date such payments are
due under this Agreement shall bear interest to the extent permitted by
applicable law at the prime rate reported by Norwest Bank, Denver, Colorado, on
the date such payment is due, calculated on the number of days such payment is
delinquent.
2.8 Taxes. Any sales, use or other taxes or other governmental
charges (excluding taxes on Array's income) incident to the transfer of
Compounds to Tularik pursuant to this Agreement shall be [ * ].
2.9 Title. Without limiting Tularik's rights under Article 3
below, it is understood and agreed that Array retains title to the TA Libraries
and Compounds delivered to Tularik under this Agreement.
2.10 Second Diversity Library. Upon receipt of a written
notice from Tularik, Array shall deliver to Tularik the small molecule compound
library described in this Section 2.10 (the "Second Diversity Library"). The
Second Diversity Library shall consist of [ * ] TA Libraries and shall contain a
total of [ * ] Compounds. Each TA Library shall contain on average [ * ] of each
Compound, and each Compound within a TA Library shall be based on the same
Scaffold. The TA Libraries within the Second Diversity Library shall be based on
such Scaffolds as the parties mutually agree upon in writing. If Tularik
provides the written notice described in the first sentence of this Section 2.10
on or prior to the [ * ] anniversary of the Effective Date, Tularik will pay
[ * ] per Compound for Compounds within the Second Diversity Library. If Tularik
provides the written notice set forth in the first sentence of this Section 2.10
more than [ * ] after the Effective Date, Tularik will pay [ * ] per Compound
for Compounds within the Second Diversity Library. In the event that Tularik
reasonably demonstrates to Array that any Compound within the Second Diversity
Library does not conform to the specifications and meet the quality control
criteria set forth on Exhibit B, Array shall refund to Tularik the price paid
pursuant to this Section 2.10 for every such non-conforming Compound. For
avoidance of doubt, the parties understand and agree that Sections 2.5, 2.7, 2.8
and 2.9 shall apply to Compounds and TA Libraries within the Second Diversity
Library.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
6
3. LICENSES; ACTIVE COMPOUNDS
3.1 Licenses.
(a) License Grant. Subject to the terms and
conditions of this Agreement, Array hereby grants to Tularik the following
licenses under the applicable Licensed Technology, (i) a non-exclusive,
worldwide royalty-free license (without the right to sublicense) to make, have
made and use the Compounds for developmental purposes and (ii) an exclusive,
worldwide royalty-free license (with the right to sublicense) to make, have
made, use, sell and import Active Compounds for applications in the Field.
(b) Sublicenses.
(i) Generally. The license granted under
Section 3.1(a)(ii) above shall include the right to grant sublicenses, but the
license granted under Section 3.1(a)(i) shall be without the right to
sublicense. Accordingly, Tularik shall not disclose or transfer any Compounds or
Compound Information to any third party except to the extent necessary to
manufacture Active Compounds or as provided in Section 3.2(b)(ii) below.
(ii) Collaboration. In the event that
Tularik establishes a Collaboration with a third party, Tularik may provide
Compounds and/or Active Compounds to such third party for use by such third
party as reasonably necessary for the purposes of such Collaboration. The
Collaboration must be evidenced by a written agreement that provides, among
other things, that the third party agrees not to provide any Compound to others
unless the same is an Active Compound hereunder.
(c) Reservation. Notwithstanding Section 3.1(a)
above, Array hereby reserves the right, including the right to authorize others,
under the Licensed Technology to make, have made, and use all Compounds for
research and/or other purposes. Notwithstanding the foregoing, for so long as a
Compound is an Active Compound, Array agrees not to provide such Active Compound
to third parties as part of a compound library or otherwise.
3.2 Designation of Active Compounds. At any time prior to the
expiration of the Selection Period applicable to a particular Compound, Tularik
shall have the right to designate the same as an Active Compound as set forth in
this Section 3.2 below. Tularik may designate up to [ * ] such Compounds as
Active Compounds hereunder at any particular time.
(a) Designation. To designate a Compound as an Active
Compound, Tularik shall so notify Array in writing, with a description of the
Compound (including a complete description of its chemical structure), and pay
the first Annual Maintenance Fee for such Active Compound pursuant to Section
3.3 below. It is understood, however, that any such designation shall be subject
to Sections 3.2(b) and 3.5 below. To the extent such designation is precluded as
described in Section 3.5 below, such Compound shall not be an Active Compound
hereunder.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
7
(b) Restriction. Tularik agrees that it shall not,
and shall not authorize any third party to, sell or otherwise commercialize any
Compound unless such Compound is an Active Compound hereunder.
3.3 Annual Maintenance Fees for Active Compounds.
(a) Maintenance Fee. To maintain Tularik's exclusive
rights to Active Compounds under Section 3.1(a)(ii) above, Tularik shall pay to
Array an annual maintenance fee for each Active Compound ("Annual Maintenance
Fee") [ * ] . The amount of the Annual Maintenance Fee will be based upon the
aggregate number of Active Compounds at any particular time, according to the
following schedule:
NUMBER OF ACTIVE COMPOUNDS ANNUAL MAINTENANCE FEE PER COMPOUND
-------------------------- -----------------------------------
First [ * ] [ * ] /Compound
Next [ * ] [ * ] /Compound
Above [ * ] [ * ] ) [ * ] /Compound
(b) Calculation. The Annual Maintenance Fees shall be
calculated on a calendar year basis. The first Annual Maintenance Fee for an
Active Compound shall be prorated based upon the number of days remaining in the
calendar year from the date of such designation. Thereafter, the Annual
Maintenance Fee for such Active Compound shall be due no later than January 15
of the particular calendar year. Once paid, an Annual Maintenance Fee shall be
nonrefundable.
(c) Proration; Redesignation. In the event that the
first Annual Maintenance Fee was prorated on the basis of less than a full
calendar year, such Annual Maintenance Fee for the [ * ] calendar year shall be
prorated from January 1 of such year until the date that is the [ * ]
anniversary of the date of designation of the particular Active Compound. If an
Active Compound is terminated, and later re-designated as an Active Compound
under Section 3.2 above, such [ * ] period shall begin as of the date of the
subsequent re-designation.
3.4 Intellectual Property.
(a) Ownership. Title to patent rights in an invention
made solely by Array personnel ("Array Invention") shall be owned by Array.
Title to patent rights in an invention made solely by Tularik personnel
("Tularik Invention") shall be owned by Tularik. Title to patent rights in an
invention made jointly by Tularik personnel and Array personnel ("Joint
Invention") shall be owned jointly by Tularik and Array. [ * ] however, in no
event shall such patent or patent application include claims to Array's
high-speed synthesis technology or methods.
(b) Patent Prosecution. Tularik shall not include any
Compound or Active Compound in any compound claim in any patent or patent
application covering a Tularik Invention. [ * ] Tularik shall (i) designate such
Compound as an Active Compound and pay an
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
8
Annual Maintenance Fee on such Active Compound pursuant to Sections 3.2 and 3.3,
respectively [ * ]. Tularik shall be solely responsible for filing, prosecuting
and maintaining any such patent or patent application at its expense and shall
keep Array reasonably informed as to the same.
(c) Infringement. In the event a third party is
infringing Array Patent Rights by reason of the manufacture, sale or use of an
Active Compound, provided that such infringement is substantial and continuing,
Tularik shall have the right to bring a lawsuit or other appropriate legal
proceeding to enforce such Array Patent Rights with respect to such
infringement. Otherwise, the parties agree that Array shall have and retain the
exclusive right to enforce Array Patent Rights (itself or through third
parties). The parties agree to cooperate with respect to the enforcement of
Array Patent Rights pursuant to this Section 3.4(c), including, upon request of
the party initiating such action (the "Initiating Party"), by joining as a
nominal party at the Initiating Party's expense, where so joining is required
for the Initiating Party to bring such suit. Any action brought in accordance
with this Section 3.4(c) shall be at the expense of the [ * ], and as between
the parties hereto, any recoveries shall be [ * ].
3.5 Third Party Rights. The Diversity Library (and the
Secondary Diversity Library, if applicable) is being provided to Tularik on a
non-exclusive basis. Provided that any particular Compound has not been
previously designated as an Active Compound by Tularik hereunder, nothing herein
shall prevent or restrict Array from (i) providing such Compound to third
parties under licenses similar to those granted to Tularik hereunder or (ii)
using such Compound for any purpose. Accordingly, Tularik's right to designate
any particular Compound as an Active Compound, and Array's grant of rights to
Tularik under this Article 3, is limited to the extent that, prior to Tularik
designating such Compound as an Active Compound hereunder, (i) a third party
(either alone or jointly with Array) has filed a patent application with respect
to such Compound or (ii) Array has granted such third party an exclusive license
with respect to such Compound. It is understood that, so long as Array complies
with the terms of this Agreement, Array shall have no liability with respect to
any conflict between Tularik's rights and rights of the nature described in this
Section 3.5 granted to a third party by Array.
3.6 Termination of Licenses. The licenses granted to Tularik
herein shall continue in perpetuity unless Tularik materially breaches this
Agreement, in which case the licenses shall terminate, provided that Tularik
does not cure any such material breach within sixty (60) days of notification of
the same by Array.
3.7 [ * ] of Active Compounds. Tularik may [ * ] of any
particular Active Compound at any time by submitting a [ * ] to Array. From and
after the date Array receives such [ * ]. Without limiting the foregoing, in the
event [ * ] Active Compound, Tularik shall promptly [ * ] to Array all [ * ]
such Active Compound. In addition, in the event that Tularik [ * ], Tularik
shall, at Array's request, [ * ] on [ * ] reasonable and customary for the
[ * ], which [ * ].
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
9
4. CONFIDENTIALITY
4.1 Confidential Information. Except as expressly provided
herein, the receiving party (hereinafter, the "Receiving Party") shall not
disclose to any third party or use for any purpose any Confidential Information
furnished to it by the other party (hereinafter the "Disclosing Party") pursuant
to this Agreement. For purposes of this Article 4, "Confidential Information"
shall mean any information disclosed by the Disclosing Party to the Receiving
Party pursuant to this Agreement. Notwithstanding the foregoing, Confidential
Information shall not include any information that, in each case as demonstrated
by written documentation: (i) was already known to the Receiving Party, other
than under an obligation of confidentiality, at the time of disclosure; (ii) was
generally available to the public or otherwise part of the public domain at the
time of its disclosure to the Receiving Party; (iii) became generally available
to the public or otherwise part of the public domain after its disclosure and
other than through any act or omission of the Receiving Party in breach of this
Agreement; (iv) was subsequently lawfully disclosed to the Receiving Party by a
third party who did not acquire it directly or indirectly from the Disclosing
Party; or (v) was developed by the Receiving Party without use of or reference
to any Confidential Information of the Disclosing Party.
4.2 Disclosure to Array. Notwithstanding Section 4.1 above, if
Tularik desires to disclose to Array Confidential Information related to (i) the
activity of a Compound in biological or other screens or targets, (ii) the
targets against which a Compound is or will be screened, or (iii) other
development or screening efforts with respect to a Compound, Array shall not
review such Confidential Information if Array does not desire to receive such
Confidential Information. Notwithstanding the foregoing provisions of this
Section 4.2, if Tularik provides to Array information within clauses (i) - (iii)
above and Array does not notify Tularik within fifteen (15) days that it does
not desire to receive such information and return all such information to
Tularik, the same shall be treated as Confidential Information of Tularik under
Section 4.1 above (subject to the exclusion of clauses (i) - (v) thereof).
4.3 Permitted Use and Disclosures. The Receiving Party may use
and disclose the Confidential Information of the Disclosing Party to the extent
necessary to exercise its rights or perform its obligations under this
Agreement, in filing or prosecuting patent applications and patents, prosecuting
or defending litigation, complying with applicable governmental regulations or
court orders or otherwise submitting information to tax or other governmental
authorities, conducting trials, or making a permitted sublicense or otherwise
exercising license rights expressly granted to the other party to it pursuant to
the terms of this Agreement, provided that if the Receiving Party is required to
make any such disclosure of the Disclosing Party's Confidential Information,
other than pursuant to a confidentiality agreement, it shall give reasonable
advance notice to the Disclosing Party of such disclosure and, save to the
extent inappropriate in the case of patent applications, shall use its
reasonable efforts to secure confidential treatment of such Confidential
Information in consultation with the Disclosing Party prior to its disclosure
(whether through protective orders or otherwise) and disclose only that portion
of the Confidential Information necessary to comply with such requirements.
4.4 Nondisclosure of Terms. Each of the parties hereto agrees
not to disclose to any third party the terms of this Agreement without the prior
written consent of the other party
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
10
hereto, except to such party's attorneys, advisors, investors and others on a
need to know basis under circumstances that reasonably ensure the
confidentiality thereof, or to the extent required by law. Notwithstanding the
foregoing, the parties shall agree upon a press release to announce the
execution of this Agreement.
4.5 Publication. Any non-confidential publication, abstract or
presentation (including information to be presented orally) by or authorized by
Tularik relating to a Compound, or derivatives thereof or products based thereon
shall be subject to the prior review and reasonable agreement of Array at least
thirty (30) days prior to submission. Without limiting the foregoing, at Array's
request, Tularik shall remove any and all Array Confidential Information
therefrom prior to publication or disclosure. The parties shall treat matters of
authorship of scientific abstracts, manuscripts or other publications in a
proper collaborative spirit, giving credit where credit is due.
5. REPRESENTATIONS AND WARRANTIES
5.1 Tularik. Tularik warrants and represents that: (i) it has
the legal power, authority and right to enter into this Agreement, and to
perform all its obligations hereunder; and (ii) this Agreement is a legal and
valid obligation binding upon it and enforceable in accordance with its terms.
5.2 Array. Array represents and warrants that: (i) it has the
legal right and power to extend the rights granted in this Agreement; (ii) it
has the legal power, authority and right to enter into this Agreement, and to
perform all its obligations hereunder; and (iii) this Agreement is a legal and
valid obligation binding upon it and enforceable in accordance with its terms.
5.3 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN
THIS ARTICLE 5, NEITHER ARRAY NOR TULARIK MAKES ANY REPRESENTATION OR WARRANTIES
OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE
DIVERSITY LIBRARY, TA LIBRARIES, COMPOUNDS OR PRODUCTS BASED THEREON, OR
INFORMATION DISCLOSED HEREUNDER, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF ANY
LICENSED TECHNOLOGY, PATENTED OR UNPATENTED, OR NONINFRINGEMENT OF THE
INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.
6. INDEMNIFICATION
6.1 Tularik. Tularik agrees to indemnify, defend and hold
Array, and its directors, officers, employees and agents harmless from and
against any losses, costs, claims, damages, liabilities or expense (including
reasonable attorneys' and professional fees and court and other expenses of
litigation) (collectively, "Liabilities") arising out of or in connection with
third party claims relating to (i) any Compounds or product based thereon
developed, manufactured, used, sold or otherwise distributed by or under
authority of Tularik or its
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
11
designees (including, without limitation, product liability claims), or (ii) any
breach by Tularik of the representations and warranties made in this Agreement,
except in each case, to the extent such Liabilities resulted from the gross-
negligence or intentional misconduct of Array.
6.2 Array. Array agrees to indemnify, defend and hold Tularik,
and its directors, officers, employees and agents harmless from and against any
losses, costs, claims, damages, liabilities or expense (including reasonable
attorneys' and professional fees and court and other expenses of litigation)
(collectively, "Liabilities") arising out of or in connection with third party
claims relating to (i) the preparation and supply of Compounds in connection
with Array's performance under this Agreement; and (ii) any breach by Array of
the representations and warranties made in this Agreement, except in each case,
to the extent such Liabilities resulted from the gross negligence or intentional
misconduct of Tularik.
6.3 Procedure. A party that intends to claim indemnification
(the "Indemnitee") under this Article 6 shall promptly notify the indemnifying
party (the "Indemnitor") in writing of any third party claim, suit or proceeding
included within the indemnification described in this Article 6 above (each a
"Claim") with respect to which the Indemnitee intends to claim such
indemnification, and the Indemnitor shall have sole control of the defense
and/or settlement thereof; provided that the Indemnitee shall have the right to
participate, at its own expense, with counsel of its own choosing in the defense
and/or settlement of such Claim. The indemnification under this Article 6 shall
not apply to amounts paid in settlement of any Claim if such settlement is
effected without the consent of the Indemnitor, which consent shall not be
unreasonably withheld or delayed. The Indemnitee under this Article 6, and its
employees, at the Indemnitor's request and expense, shall provide full
information and reasonable assistance to Indemnitor and its legal
representatives with respect to such Claims.
7. TERM AND TERMINATION
7.1 Term. This Agreement shall become effective on the
Effective Date and shall remain in full force and effect until expiration of the
Selection Period for the last Compound delivered hereunder, unless earlier
terminated in accordance with this Article 7 below.
7.2 Termination for Cause. Either party to this Agreement
shall have the right to terminate this Agreement in the event the other party
materially breaches or defaults in the performance of any of its material
obligations hereunder, and such default continues for sixty (60) days after
written notice thereof is provided to the breaching party by the non-breaching
party. Any such termination shall become effective at the end of such sixty (60)
day period unless the breaching party (or any other party on its behalf) has
cured any such breach or default prior to the expiration of the sixty (60) day
period; provided in the case of a failure to pay any amount due hereunder, such
default may be the basis of termination thirty (30) days following the date that
notice of such default was provided to the breaching party.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
12
7.3 Termination for Insolvency. If voluntary or involuntary
proceedings by or against a party are instituted in bankruptcy under any
insolvency law, or a receiver or custodian is appointed for such party, or
proceedings are instituted by or against such party for corporate reorganization
or the dissolution of such party, which proceedings, if involuntary, shall not
have been dismissed within sixty (60) days after the date of filing, or if such
party makes an assignment for the benefit of creditors, or substantially all of
the assets of such party are seized or attached and not released within sixty
(60) days thereafter, the other party may immediately terminate this Agreement
effective upon notice of such termination.
7.4 Effects.
(a) Accrued Liability. It is understood that
termination of this Agreement shall not relieve a party from any liability
which, at the time of such termination, has already accrued to the other party.
(b) Survival. The provisions of Articles 1, 4, 6 and
8 and Sections 3.4, 3.5, 3.6, 3.7 and 7.4 shall survive the expiration or
termination of this Agreement for any reason. In addition, the provisions of
Sections 2.1, 3.1 and 3.3 shall survive the expiration or termination of this
Agreement for cause by Tularik following breach by Array but not termination for
cause by Array following breach by Tularik. All other rights and obligations of
the parties shall cease upon expiration or termination of this Agreement. For
purposes of the foregoing, if a Section that so survives is expressly stated to
continue for a period of time specified in such surviving Section, the same
shall survive only for the remainder of the period specified in such Section.
Except as otherwise expressly provided in this Article 7, all other rights and
obligations of the parties shall terminate.
8. MISCELLANEOUS
8.1 Governing Laws. This Agreement and any dispute arising
from the construction, performance or breach hereof shall be governed by and
construed and enforced in accordance with the laws of the state of Colorado,
without reference to conflicts of laws principles.
8.2 No Implied Licenses. Nothing herein shall be construed as
granting either party, by implication, estoppel or otherwise, any license or
other right to any intellectual property, except for the licenses expressly
granted herein.
8.3 Waiver. Any waiver of the terms and conditions hereof must
be explicitly in writing. The waiver by either party of any breach of any
provision hereof by the other party shall not be construed to be a waiver of any
succeeding breach of such provision or a waiver of the provision itself.
8.4 Assignment. The parties agree that their rights and
obligations under this Agreement may not be assigned or otherwise transferred to
a third party without the prior written consent of the other party hereto.
Notwithstanding the foregoing, either party may transfer or
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
13
assign its rights and obligations under this Agreement to a successor to all or
substantially all of its business or assets relating to this Agreement whether
by sale, merger, operation of law or otherwise; provided that such assignee or
transferee has agreed in writing to be bound by the terms and conditions of this
Agreement. Any attempted transfer or assignment in violation of this Section 8.4
shall be void. Subject to the foregoing, this Agreement shall be binding upon
and inure to the benefit of the parties hereto, their successors and assigns.
8.5 Independent Contractors. The relationship of the parties
hereto is that of independent contractors. The parties hereto shall not be
deemed to be agents, partners or joint venturers for any purpose as a result of
this Agreement or the transactions contemplated thereby.
8.6 Compliance with Laws. In exercising their rights under
this Agreement, each party shall fully comply in all material respects with the
requirements of any and all applicable laws, regulations, rules and orders of
any governmental body having jurisdiction over the exercise of rights hereunder
including, without limitation, those applicable to the discovery, development,
manufacture, distribution, import and export and sale of products pursuant to
this Agreement.
8.7 Notices. Any notice required or permitted to be given or
made under this Agreement by either party shall be in writing and delivered to
the other party at its address indicated below (or to such other address as a
party may specify by notice hereunder by courier or by registered or certified
airmail, postage prepaid, or by facsimile; provided, however, that all facsimile
notices shall be promptly confirmed, in writing, by registered or certified
airmail, postage prepaid. All notices shall be effective as of the date received
by the addressee.
if to Array, to: Array BioPharma Corporation
0000 00xx Xxxxxx
Xxxxxxx, Xxxxxxxx 00000
Fax number: (000) 000-0000
with a copy to: Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx
000 Xxxx Xxxx Xxxx
Xxxx Xxxx, Xxxxxxxxxx 00000-0000
Attn: Xxxxxxx X. Xxxxx, Esq.
Fax number: (000) 000-0000
if to Tularik, to: Tularik Inc.
Xxx Xxxxxxxxx Xxxxx
Xxxxx Xxx Xxxxxxxxx, XX 00000
Attn: General Counsel
Fax number: (000) 000-0000
8.8 Severability. In the event that any provision of this
Agreement becomes or is declared by a court of competent jurisdiction to be
illegal, unenforceable or void, this
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
14
Agreement shall continue in full force and effect without said provision, and
the parties shall amend the Agreement to the extent feasible to lawfully include
the substance of the excluded provision to as fully as possible realize the
intent of the parties and their commercial bargain, unless the invalid
provision(s) are of such essential importance to this Agreement that it is to be
reasonably assumed that the parties would not have entered into this Agreement
without the invalid provision(s).
8.9 Force Majeure. Nonperformance of either party (except for
payment obligations) shall be excused to the extent that performance is rendered
impossible by acts of God, strike, fire, earthquake, flood, governmental acts or
orders or restrictions, failure of suppliers, or any other reason where failure
to perform is beyond the reasonable control and not caused by the negligence,
intentional conduct or misconduct of the non-performing party, provided such
party uses its best efforts to resume performance as promptly as possible.
8.10 No Consequential Damages. EXCEPT PURSUANT TO ARTICLE 6,
NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL,
EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR
PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS
AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE)
OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF
THE POSSIBILITY OR LIKELIHOOD OF SAME. THESE LIMITATIONS SHALL APPLY
NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY LIMITED REMEDY, AND
THE PARTIES ACKNOWLEDGE THAT THIS SECTION 8.10 REPRESENTS A REASONABLE
ALLOCATION OF RISK.
8.11 Further Assurances. At any time and from time to time
after the Effective Date, each party hereby agrees to execute, acknowledge and
deliver, and cause to be done, executed, acknowledged or delivered, and take or
cause to be taken all such further acts, transfers, conveyances, or assignments
as may be reasonably required to carry out the transactions contemplated by this
Agreement.
8.12 Headings. Headings included herein are for convenience
only, do not form a part of this Agreement and shall not be used in any way to
construe or interpret this Agreement.
8.13 Entire Agreement. The terms and provisions contained in
the Agreement, including the Exhibits hereto, constitute the entire agreement
between the parties and shall supersede all previous communications,
representations, agreements or understandings, either oral or written, between
the parties with respect to the subject matter hereof. No agreement or
understanding varying or extending this Agreement shall be binding upon either
party hereto, unless set forth in a writing which specifically refers to the
Agreement signed by duly authorized officers or representatives of the
respective parties, and the provisions hereof not specifically amended thereby
shall remain in full force and effect. ANY ADDITIONAL OR
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
15
INCONSISTENT TERMS OR CONDITIONS OF ANY PURCHASE ORDER, ACKNOWLEDGMENT OR
SIMILAR STANDARDIZED FORM GIVEN OR RECEIVED PURSUANT TO THIS AGREEMENT SHALL
HAVE NO EFFECT AND SUCH TERMS AND CONDITIONS ARE HEREBY EXCLUDED.
8.14 Counterparts. This Agreement may be executed in
counterparts, each of which shall be deemed to be an original and all of which
together shall be deemed to be one and the same agreement.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed by their authorized representatives and delivered in duplicate
originals as of the Effective Date.
ARRAY BIOPHARMA INC. TULARIK INC.
By: /s/ Xxxxx Snitmann By: /s/ Xxxx X. XxXxxxxxxx
--------------------------- ----------------------------------
Name: Xxxxx Snitmann Name: Xxxx X. XxXxxxxxxx
------------------------- --------------------------------
Title: COO Title: President
------------------------ -------------------------------
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
16
EXHIBIT A
TEMPLATE ARRAY LIBRARY SCAFFOLDS
[ * ]
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
17
EXHIBIT B
COMPOUND SPECIFICATIONS/QUALITY CONTROL
[ * ]
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
18
EXHIBIT C
HIT EXPLOSION LIBRARY AGREEMENT
TERM SHEET
[ * ]
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
